Invention Grant
- Patent Title: Pharmaceutical compositions for direct systemic introduction
-
Application No.: US16117407Application Date: 2018-08-30
-
Publication No.: US10695332B2Publication Date: 2020-06-30
- Inventor: Mark Ridall , David Rock
- Applicant: NewMarket Pharmaceuticals LLC
- Applicant Address: US NJ Trenton
- Assignee: NewMarket Pharmaceuticals LLC
- Current Assignee: NewMarket Pharmaceuticals LLC
- Current Assignee Address: US NJ Trenton
- Agency: Cadwalader, Wickersham & Taft LLP
- Main IPC: A61K9/20
- IPC: A61K9/20 ; A61K31/4439 ; A61K9/00

Abstract:
The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.
Public/Granted literature
- US20180369221A1 PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTION Public/Granted day:2018-12-27
Information query